Biology subjects

Orcutt-Jahns, B.

Publications and source records attributed to Orcutt-Jahns, B..

6 recordsLinked to original sources

bioRxiv2026

Tissue retention of dendritic cells drives age-associated protective tolerogenic lymphoid structures

Ectopic lymphoid structures are typically associated with chronic tissue inflammation in autoimmunity and cancer, where they can amplify local immune responses. Similar structures arise spontaneously with age, yet their origin and function remain unclear. Here we identify tissue retention of mature migratory conventional dendritic cells (cDCs) as a driver of age-associated lymphoid organization. Mature cDCs accumulated within lymphoid structures in aged human and mouse tissues. We demonstrate that impaired cDC egress or pharmacological cDC expansion induced de novo structures in mice across multiple otherwise homeostatic organs without associated pathology. Strikingly, senescence-associated tissue cues, which promoted a distinct cDC maturation state, were required for lymphoid niche initiation. Unlike inflammatory structures described in disease, these cDC-driven structures preferentially accumulated tissue-adapted regulatory T cells and protected against inflammatory injury, revealing a previously unrecognized regulatory dimension of age-associated lymphoid organization.

immunology↗

bioRxiv2026

Linking live-cell behavior to transcriptional responses across perturbations using dynamic caging

Single-cell technologies, encompassing molecular, morphological, and functional assays, have emerged as cornerstones of modern biological research and discovery. However, current experimental methods often fail to explicitly link these omic modalities, especially in live cells or longitudinally through time, impeding the study of multi-scale interactions and mechanisms of regulation. CellCage Enclosure (CCE) technology overcomes these limitations by dynamically compartmentalizing cells, allowing for scalable, live-cell, longitudinal exploration and simultaneous analysis of transcriptomic, proteomic, and morphological profiles. Using this novel technology, we generate previously inaccessible insights across various in vitro cellular systems under a diverse set of perturbations, including the discovery of morphological and proteomic features linked to immune suppressive gene set expression in human primary regulatory T cells (Tregs), as well as direct association of morphological and proteomic features with inflammatory gene modules in human colonic fibroblasts. We then develop a novel pooled CRISPR genetic screening technology using CCEs, PERTURB-LINK (PERTURBational LINKage of transcriptomics and imaging in single cells via enclosure-based screening) and apply this approach in murine bone marrow derived macrophages (BMDMs), enabling multiomic dissection of NF-{kappa}B pathway regulation in response to lipopolysaccharide (LPS) stimulation. Together, these findings demonstrate the broad impact that advancements in live-cell, paired multimodal technologies, especially upon perturbation, may offer in deepening our understanding of cellular biology.

cell biology↗

bioRxiv2026

Agentic systems are adept at solving well-scoped, verifiable problems in computational biology

We introduce CompBioBench, a benchmark of 100 diverse tasks for evaluating agentic systems in computational biology. Unlike mathematics and programming, which more readily admit systematic verification, biological data are inherently noisy and open to interpretation. To enable objective evaluation without reducing tasks to prescriptive checklists, we propose a new benchmark construction strategy based on synthetic/augmented data and metadata scrambling/scrubbing of real datasets to create challenging problems that have a single ground-truth answer and require multi-step reasoning, tool use, bespoke code, and interaction with real-world external resources. The benchmark spans genomics, transcriptomics, epigenomics, single-cell analysis, human genetics, and machine learning workflows. Questions are curated by domain experts to cover a broad range of skills with varying difficulty. We evaluate leading general-purpose agentic systems starting from a bare-minimum environment, requiring them to fetch data and tools as needed to solve each problem. We find strong end-to-end performance, with Codex CLI (GPT 5.4) reaching 83% accuracy, Gemini CLI (3.1 Pro) reaching 82%, Claude Code (Opus 4.6) reaching 81%, and Claude Code (Opus 4.7) reaching 78%. On the hardest questions, Claude Code (Opus 4.6) reaches 69%, Codex CLI (GPT 5.4) reaches 59%, and Gemini CLI (3.1 Pro) reaches 49%. CompBioBench provides a practical testbed for measuring the progress of agentic systems in computational biology and for guiding future benchmark design. Data and a public leaderboard are available at https://huggingface.co/collections/Genentech/compbiobench-v1.

bioinformatics↗

bioRxiv2023

Systems profiling reveals recurrently dysregulated cytokine signaling responses in ER+ breast cancer patients' blood

Cytokines mediate cell-to-cell communication across the immune system and therefore are critical to immunosurveillance in cancer and other diseases. Several cytokines show dysregulated abundance or signaling responses in breast cancer, associated with the disease and differences in survival and progression. Cytokines operate in a coordinated manner to affect immune surveillance and regulate one another, necessitating a systems approach for a complete picture of this dysregulation. Here, we profiled cytokine signaling responses of peripheral immune cells from breast cancer patients as compared to healthy controls in a multidimensional manner across ligands, cell populations, and responsive pathways. We find alterations in cytokine responsiveness across pathways and cell types that are best defined by integrated signatures across dimensions. Alterations in the abundance of a cytokines cognate receptor do not explain differences in responsiveness. Rather, alterations in baseline signaling and receptor abundance suggesting immune cell reprogramming are associated with altered responses. These integrated features suggest a global reprogramming of immune cell communication in breast cancer. Significance StatementWhile individual cytokine responses have previously been observed to be altered in breast cancer, cytokine signaling responses are tightly interconnected in a way that has not been previously characterized. Here, we profile cytokine signaling responses and find alterations that are shared across both pathways and cell types. The signatures across these measurements better define the alterations and point to a broad immunosuppression response. HighlightsO_LIBaseline and post-stimulation cytokine signaling profiles differ between healthy donors and breast cancer patients. C_LIO_LIChanges in cytokine response are not explained by differences in abundance of the cognate receptor C_LIO_LIFeatures of signaling response and receptor abundance dysregulation are coordinated across patients C_LIO_LIIntegrated patterns of dysregulation in breast cancer patients share features of Th17 like-response as well as regulatory-like B and CD8+ T cells C_LI

cancer biology↗

bioRxiv2021

Multivalency enhances the specificity of Fc-cytokine fusions

The common {gamma}-chain receptor cytokines coordinate the proliferation and function of immune cell populations. One of these cytokines, interleukin (IL)-2, has potential as a therapy in autoimmune disease but is limited in effectiveness by its modest specificity toward regulatory T cells (Tregs). Engineering Treg-selective IL-2 has primarily focused on retaining binding to the high-affinity receptor, expressed more highly on Tregs, while reducing binding to the lower affinity receptor with broader expression. However, other parameters, such as the orientation and valency of Fc fusion, have signaling effects that have never been systematically explored. Here, we systematically profiled the signaling responses to a panel of wild type and mutein IL-2-Fc fusions across time, cell types, and concentrations. Exploring these responses, we found that dimeric muteins have unique specificity for Tregs through binding avidity. A mechanistic model of receptor interactions could capture these effects and directed the design of tetravalent IL-2-Fc fusions with greater Treg specificity than possible with current design strategies. Exploration of other surface targets on Tregs revealed that there are no other binding moieties that could be fused to IL-2 for greater selectivity. Instead, IL2R itself is a maximally unique surface target for Tregs, and so avidity is likely the only route to more selective Treg interaction. However, the binding model revealed that asymmetrical, multivalent IL-2 fusions can bias avidity effects toward IL2R for even further enhanced Treg selectivity. These findings present a comprehensive analysis of how ligand properties and their effects on surface receptor-ligand interactions translate to selective activation of immune cell populations, and consequently reveals two new routes toward therapeutic cytokines with superior Treg selectivity that can be exploited for designing selective therapies in many other contexts. Significance StatementSignaling in off-target immune cells has hindered the effectiveness of IL-2 as an immunotherapy. We show that IL-2-Fc fusions with higher valency can exhibit enhanced regulatory T cell selectivity. This altered selectivity is explained by the kinetics of surface receptor-ligand binding and can be quantitatively predicted using a multivalent binding model. Using these insights, we successfully develop two new strategies for IL-2 therapies with unprecedented selectivity. HighlightsO_LICurrent IL-2 therapies are limited by a selectivity/target potency tradeoff. C_LIO_LIMultivalency enhances selectivity for Tregs through IL2R avidity. C_LIO_LITreg selectivity cannot be enhanced by targeting other surface protein markers. C_LIO_LIMultivalency can decouple selectivity from signaling using asymmetric cytokine fusions. C_LI

immunology↗

bioRxiv2020

A quantitative view of strategies to engineer cell-selective ligand binding

A critical property of many therapies is their selective binding to specific target populations. Exceptional specificity can arise from high-affinity binding to unique cell surface targets. In many cases, however, therapeutic targets are only expressed at subtly different levels relative to off-target cells. More complex binding strategies have been developed to overcome this limitation, including multi-specific and multi-valent molecules, but these create a combinatorial explosion of design possibilities. Therefore, guiding strategies for developing cell-specific binding are critical to employ these tools. Here, we extend a multi-valent binding model to multi-ligand and multi-receptor interactions. Using this model, we explore a series of mechanisms to engineer cell selectivity, including mixtures of molecules, affinity adjustments, and valency changes. Each of these strategies maximizes selectivity in distinct cases, leading to synergistic improvements when used in combination. Finally, we identify situations in which selectivity cannot be derived through passive binding alone to highlight areas in need of new developments. In total, this work uses a quantitative model to unify a comprehensive set of design guidelines for engineering cell-specific therapies. Summary pointsO_LIAffinity, valency, and other alterations to target cell binding provide enhanced selectivity in specific situations. C_LIO_LIEvidence for the effectiveness and limitations of each strategy are abundant within the drug development literature. C_LIO_LICombining strategies can offer enhanced selectivity. C_LIO_LIA simple, multivalent ligand-receptor binding model can help to direct therapeutic engineering. C_LI

bioengineering↗